非小细胞肺癌中转录因子SOX2的表达及其临床意义

摘要
图/表
参考文献(25)
相关文章 (15)

全文: PDF (603 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨转录因子SOX2在非小细胞肺癌（NSCLC）中的表达与其临床病理特征及预后间的联系。方法收集2017年1月—2019年5月成都医学院第一附属医院行手术切除并经病理科确诊的NSCLC标本74例。采用免疫组织化学法检测SOX2在NSCLC组织及癌旁组织的表达情况，并分析其临床病理特征及患者预后。结果 NSCLC组织SOX2阳性表达率高于癌旁组织，差异有高度统计学意义（P < 0.01）。不同组织学类型、有无淋巴结转移、不同临床分期SOX2阳性率比较，差异有统计学意义（P < 0.05或P < 0.01）。本研究从2017年4月开始随访，随访截至2020年4月。SOX2阳性表达的NSCLC患者生存期长于SOX2阴性表达者，差异有高度统计学意义（P ＜ 0.01）。SOX2阳性表达及淋巴结转移是NSCLC患者预后的独立影响因素（RR > 1，P < 0.05）。结论 NSCLC组织中SOX2表达和组织学类型及临床分期相关，可作为NSCLC诊断及判断预后的潜在生物标志物。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	杨芳1 李鹏程1 刘薇1 周艳刚1 王晓燕2 任涛1

关键词 ：非小细胞肺癌, SOX2, 临床病理特征, 预后

Abstract：Objective To investigate the expression between transcription factor SOX2 in non-small cell lung cancer (NSCLC) and association clinicopathological characteristics and prognosis. Methods From January 2017 to May 2019, 74 NSCLC specimens were collected from the First Affiliated Hospital of Chengdu Medical College and confirmed by the pathology department. Immunohistochemistry was used to detect the expression of SOX2 in NSCLC tissues and paracancerous tissues, and its clinicopathological characteristics and the prognosis of patients were analyzed. Results The positive rate of SOX2 in NSCLC tissues was higher than that in paracarcinoma tissues, and the difference was highly statistically significant (P < 0.01). There were statistically significant differences in SOX2 positive rate among different histological types, lymph node metastasis and clinical stages (P < 0.05 or P < 0.01). This study was followed up from April 2017，and follow-up was conducted up to April 2020. NSCLC patients with SOX2 positive expression lived longer than that with SOX2 negative expression, and the difference was highly statistically significant (P < 0.01). SOX2 positive expression and lymph node metastasis were independent influence factors in prognosis of patients with NSCLC (RR > 1, P < 0.05). Conclusion SOX2 expression in NSCLC tissues is related to histological type and clinical stage, which can be used as a potential biomarker for diagnosis and prognosis of NSCLC.

Key words： Non-small cell lung cancer SOX2 Clinicopathological characteristics Prognosis

基金资助:四川省科技厅应用基础研究项目（2020YJ0451）；
成都医学院第一附属医院高层次人才科研启动基金项目（CYFY-GQ22）；
成都医学院第一附属医院专项科研基金项目（CYFY2019ZD03）；
四川省医学重点学科培育学科。

通讯作者: 任涛（1977.1-），男，博士，主任医师；研究方向：肺癌的基础与临床。

作者简介: 杨芳（1992.2-），女，硕士；研究方向：肿瘤临床放疗与化疗。

引用本文:

杨芳1 李鹏程1 刘薇1 周艳刚1 王晓燕2 任涛1. 非小细胞肺癌中转录因子SOX2的表达及其临床意义[J]. 中国医药导报, 2021, 18(11): 29-32.
YANG Fang1 LI Pengcheng1 LIU Wei1 ZHOU Yan’gang1 WANG Xiaoyan2 REN Tao1. Expression of transcription factor SOX2 in non-small cell lung cancer and its significance. 中国医药导报, 2021, 18(11): 29-32.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2021/V18/I11/29

[1] Siegel RL，Miller KD，Jemal A. Cancer statistics，2020 [J]. CA Cancer J Clin，2020，70（1）：7-30.
[2] Torre LA，Siegel RL，Jemal A. Lung Cancer Statistics [J]. Adv Exp Med Biol，2016，893：1-19.
[3] Wen Y，Hou Y，Huang Z，et al. SOX2 is required to maintain cancer stem cells in ovarian cancer [J]. Cancer Sci，2017，108（4）：719-731.
[4] Liu K，Xie F，Gao A，et al. SOX2 regulates multiple malignant processes of breast cancer development through the SOX2/miR-181a-5p，miR-30e-5p/TUSC3 axis [J]. Mol Cancer，2017，16（1）：62.
[5] Lee SH，Oh SY，Do SI，et al. SOX2 regulates self-renewal and tumorigenicity of stem-like cells of head and neck squamous cell carcinoma [J]. Br J Cancer，2014，111（11）：2122-2130.
[6] Que J，Luo X，Schwartz RJ，et al. Multiple roles for Sox2 in the developing and adult mouse trachea [J]. Development，2009，136（11）：1899-1907.
[7] Schaal CM，Bora-Singhal N，Kumar DM，et al. Regulation of Sox2 and stemness by nicotine and electronic-cigarettes in non-small cell lung cancer [J]. Mol Cancer，2018，17（1）：149.
[8] Sholl LM，Barletta JA，Yeap BY，et al. SOX2 protein expression is an independent poor prognostic indicator in stage Ⅰ lung adenocarcinoma [J]. Am J Surg Pathol，2010， 34（8）：1193-1198.
[9] Sasaki H，Yokota K，Hikosaka Y，et al. Increased Sox2 copy number in lung squamous cell carcinomas [J]. Exp Ther Med，2012，3（1）：44-48.
[10] Wilbertz T，Wagner P，Petersen K，et al. SOX2 gene am plification and protein overexpression are associated with better outcome in squamous cell lung cancer [J]. Mod Pathol，2011，24（7）：944-953.
[11] Ying J，Shi C，Li CS，et al. Expression and significance of SOX2 in non-small cell lung carcinoma [J]. Oncol Lett，2016，12（5）：3195-3198.
[12] Li Q，Liu F，Zhang Y，et al. Association of SOX2 and Nestin DNA amplification and protein expression with clinical features and overall survival in non-small cell lung cancer：A systematic review and meta-analysis [J]. Oncotarget，2016，7（23）：34520-34531.
[13] Velcheti V，Schalper K，Yao X，et al. High SOX2 levels predict better outcome in non-small cell lung carcinomas [J]. PLoS One，2013，8（4）：e61427.
[14] Chen SS，Li K，Wu J，et al. Stem signatures associated antibodies yield early diagnosis and precise prognosis predication of patients with non-small cell lung cancer [J]. J Cancer Res Clin Oncol，2021,147（1）：223-233.
[15] Bora-Singhal N，Mohankumar D，Saha B，et al. Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2 [J]. Sci Rep，2020，10（1）：4722.
[16] Chen WW，Gong KK，Yang LJ，et al. Scutellariabarbata D. Don extraction selectively targets stemness-prone NSCLC cells by attenuating SOX2/SMO/GLI1 network loop [J]. J Ethnopharmacol，2020，265：113295.
[17] Yang YG，Koh YW，Sari IN，et al. Interferon-induced transmembrane protein 1-mediated EGFR/SOX2 signaling axis is essential for progression of non-small cell lung cancer [J]. Int J Cancer，2019，144（8）：2020-2032.
[18] Choe C，Kim H，Min S，et al. SOX2，a stemness gene，induces progression of NSCLC A549 cells toward anchorage-independent growth and chemoresistance to vinblastine [J]. Onco Targets Ther，2018，11：6197-6207.
[19] Hur JY，Kim HR，Lee JY，et al. CDK7 inhibition as a promising therapeutic strategy for lung squamous cell carcinomas with a SOX2 amplification [J]. Cell Oncol（Dordr），2019，42（4）：449-458.
[20] Yuan XW，Wang DM，Hu Y，et al. Hepatocyte nuclear factor 6 suppresses the migration and invasive growth of lung cancer cells through p53 and the inhibition of epithelial-mesenchymal transition [J]. J Biol Chem，2013， 288（43）：31206-31216.
[21] Wang RH，Zhu XJ，Wang Q，et al. The anti-tumor effect of taxifolin on lung cancer via suppressing stemness and epithelial-mesenchymal transition in vitro and oncogenesis in nude mice [J]. Ann Transl Med，2020，8（9）：590.
[22] Chang Z. Downregulation of SOX2 may be targeted by miR-590-5p and inhibits epithelial-to-mesenchymal transition in non-small-cell lung cancer [J]. Exp Ther Med，2019，18（2）：1189-1195.
[23] Zhang KW，Li Y，Qu LM，et al. Long noncoding RNA Sox2 overlapping transcript（SOX2OT）promotes non-small-cell lung cancer migration and invasion via sponging microRNA 132（miR-132）[J]. Onco Targets Ther，2018，11：5269-5278.
[24] Gao W，Qi CQ，Feng MG，et al. SOX2-induced upregulation of lncRNA LINC01561 promotes non-small-cell lung carcinoma progression by sponging miR-760 to modulate SHCBP1 expression [J]. J Cell Physiol，2020， 235（10）：6684-6696.
[25] Wang FF，Wang S，Xue WH，et al. microRNA-590 suppresses the tumorigenesis and invasiveness of non-small cell lung cancer cells by targeting ADAM9 [J]. Mol Cell Biochem，2016，423（1/2）：29-37.